Patients with a history of myocardial infarction (MI) are at very high risk of subsequent cardiovascular events. Adequate lipid-lowering therapy (LLT) helps prevent such events.

In patients with a history of MI who started an LLT (statin and/or ezetimibe), each 10% increase in treatment intensity, adherence, or adherence-adjusted intensity is associated with a decrease in the risk of major adverse cardiovascular events (MI, stroke, or cardiovascular death) of 17% (HR = 0.83, 95% CI 0.79–0.87), 5% (HR = 0.95, 95% CI 0.94–0.97), and 14% (HR = 0.86, 95% CI 0.83–0.90), respectively.

Higher treatment intensity and/or adherence of LLT was associated with significantly lower risk of major adverse cardiovascular events in post-MI patients.